CCRL2/CRAM-A/B Antibody (BZ5B8) [CoraFluor™ 1]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-11981CL1
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Mouse
Applications
ELISA, Flow Cytometry, Functional Assay, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunoprecipitation, Western Blot
Label
CoraFluor 1
Antibody Source
Recombinant Monoclonal Rat IgG2a Kappa Clone # BZ5B8
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
This antibody was raised by immunising Wistar Furth rats with the mCCRL2/CRAM-A/B peptide/KLH conjugate. The immunizing amino-terminal mCCRL2/CRAM-A/B peptide with the sequence NH2-MDNYTVAPDDEYDVLILDDYLDNSC-COOH, corresponding to residues 1-24 of mCCRL2/CRAM-A/B, with a nonnative carboxyl-terminal cysteine to facilitate conjugation to keyhole limpet hemocyanin (KLH).
Specificity
This antibody is specific for murine CCRL2/CRAM-A/B (formerly known as L-CCR), which is expressed on mast cells, activated macrophages, and endothelial cells. This receptor binds the leukocyte chemoattractant chemerin without triggering classical GPCR signaling, providing a specific mechanism for local enrichment of chemerin at inflammatory sites. CCRL2/CRAM-A/B presents active chemerin to leukocytes expressing the chemoattractant receptor CMKLR1/Chemr23. Chemerin can block anti-CCRL2/CRAM-A/B antibody binding.
Clonality
Monoclonal
Host
Rat
Isotype
IgG2a Kappa
Description
CoraFluor(TM) 1 is a high performance terbium-based TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) or TRF (Time-Resolved Fluorescence) donor for high throughput assay development. CoraFluor(IM) 1 absorbs UV light at approximately 340 nm, and emits at approximately 490 nm, 545 nm, 585 nm and 620 nm. It is compatible with common acceptor dyes that absorb at the emission wavelengths of CoraFluor(TM) 1. CoraFluor(TM) 1 can be used for the development of robust and scalable TR-FRET binding assays such as target engagement, ternary complex, protein-protein interaction and protein quantification assays.
Applications for CCRL2/CRAM-A/B Antibody (BZ5B8) [CoraFluor™ 1]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional Assay
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark. Do not freeze.
Background: CCRL2/CRAM-A/B
Long Name
CC Chemokine Receptor-like 2
Alternate Names
ACKR5, CCRL2, CKRX, CRAM-A, CRAM-B, CRAMA, CRAMB, HCR
Gene Symbol
CCRL2
Additional CCRL2/CRAM-A/B Products
Product Documents for CCRL2/CRAM-A/B Antibody (BZ5B8) [CoraFluor™ 1]
Product Specific Notices for CCRL2/CRAM-A/B Antibody (BZ5B8) [CoraFluor™ 1]
CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...